AstraZeneca AZN · NYSE
$171.49 -0.63% (-$1.08)
Summary
70 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 46% a year over the last 3 years.
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- Revenue growth is slowing: 9.8% a year over the last 3 years against 17% over 5 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 25.6 USD for 1 USD of yearly profit. Over the last five years it was 326.3 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 9.8% a year. For the next fiscal year analysts expect revenue to grow by 7.2%. Earnings per share grew by 46% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 18 USD
- Research and development 25 USD
- Sales and administration 35 USD
- Taxes and other 5.7 USD
- Net profit 17 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.87%
- Paid out of profit
- 48%
- Raised in a row
- 4 years
You receive $3.23 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 20
- Hold 15
- Sell 6
Today's price within the analysts' price targets
The average target of $186.67 is 8.9% above today's price. 49% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Total Oncology 24%
- CVRM 13%
- Rare Disease 9.2%
- Farxiga 8.5%
- Tagrisso 7.3%
- Other 38%
By region
- The Americas 47%
- Europe excluding the United Kingdom 23%
- Asia, Africa And Australasia 23%
- UNITED KINGDOM 7.4%
Total Oncology brings in 24% of revenue. Farxiga grew fastest, by 24% a year.
Segments in detail